市場調查報告書
商品編碼
1403457
到 2030 年西方印漬術市場預測:按產品、應用、最終用戶和地區進行的全球分析Western Blotting Market Forecasts to 2030 - Global Analysis By Product (Consumables, Instruments and Other Products), Application (Clinical Diagnostics, Food & Beverages and Other Applications), End User and By Geography |
根據 Stratistics MRC 的數據,2023 年全球西方印漬術市場規模將達到 11.8 億美元,預計到 2030 年將達到 21.1 億美元,預測期內複合年成長率為 8.7%。
蛋白質分析和檢測是稱為西方印漬術的分子生物學技術的常見應用。西方印漬術涉及使用凝膠電泳按大小分離蛋白質,然後將分離的蛋白質轉移到膜上。西方印漬術在許多科學領域中用於研究蛋白質表現、轉譯後修飾和相互作用。
根據美國疾病管制與預防美國(CDC)公佈的資料,2020年美國將有30,635人被診斷出感染愛滋病毒。
蛋白質西方印漬術生物學和癌症等領域產生了重要的新認知。隨著生物醫學研究領域的發展和對精確蛋白質分析的需求的增加,西方印漬術變得至關重要。此外,西方印漬術在探索疾病、了解分子機制和檢驗研究結果方面的多功能性使其成為滿足生物醫學研究界不斷變化的需求的基本工具。
西方印漬術的成本有多種原因,包括需要使用昂貴的試劑和消耗品,包括封閉劑、檢測基材和抗體。成像設備和凝膠電泳系統等專用工具也會增加整體成本。此外,該技術需要熟練的人員,進一步增加了成本。執行此類測試的高成本是該市場的主要障礙。
美國衛生研究院 (NIH) 等政府機構的舉措為涉及西方印漬術技術的計分類配資金。這種支持鼓勵了生物醫學、藥物開發和診斷領域的創新、技術進步和新應用的探索。此外,財政支持還透過為蛋白質分析及相關研究的發展創造有利的環境、加速科學發現和提高可及性來提供支持,這是市場擴張的驅動力。
實驗室之間在程序、試劑和設備方面的不相容性阻礙了結果的再現性。調查方法的差異會影響資料的可靠性,並使調查結果難以比較和檢驗。標準化不良會損害西方印漬術的形象,引發資料準確性問題,並使研究團隊難以合作。
供應鏈中斷、物流挑戰以及實驗室活動的限制阻礙了西方印漬術試劑和設備的生產和分銷。由於封鎖,許多研究計劃被推遲或停止,影響了對這些產品的需求。此外,與 COVID-19 無關的研究經費減少也限制了可用於西方印漬術研究的資源。最終,隨著研究重點轉向 COVID-19,注意力和資源從其他領域轉移。經濟不確定性正在推動科學界的成本意識並影響購買決策。
由於其在分子生物學和蛋白質研究中的重要作用,設備部分預計將佔據最大佔有率。它在準確分離、運輸和檢測複雜生物樣品中的蛋白質方面發揮著至關重要的作用。製造商不斷創新,為研究人員提供尖端系統,這些系統融合了快速電泳、半乾式或濕式轉印功能以及先進的成像技術等功能。此外,這些儀器包括根據大小分離蛋白質的電泳系統、運輸蛋白質的轉移系統以及可視化和量化蛋白質條帶的成像系統。我們正在推動這一領域的擴展。
生物製藥和生物技術公司領域預計在預測期內複合年成長率最高,因為它用於藥物開發、品管和研究方法中的蛋白質分析。此技術有助於評估蛋白質表現、檢驗治療標靶並確保產品一致性。此外,它還透過提供對蛋白質特性的精確見解來支持生物製藥開發和生物技術研究的進步。它是生物製藥開發和生產的主要相關人員,並正在推動該領域的成長。
由於政府支持科學研究和開發的計劃,特別是在生物技術和醫療保健領域,北美在預測期內獲得了最大的市場佔有率。學術機構、研究機構和產業相關人員之間的合作促進創新和應用。此外,這些產品目前符合食品藥物管理局(FDA)等機構制定的法規結構規定的品質標準,確保了它們在研究和診斷方面的可靠性,從而擴大了該地區的市場。我們正在擴大規模。
由於生命科學研究中檢測技術、轉移策略和凝膠電泳系統的進步,預計歐洲在預測期內將呈現最高的複合年成長率。歐洲促進研究和開發的政策,加上支持生物技術和醫療保健創新的舉措,現在正在使這些程序更加準確和高效。 Boster Biological Technology、GE Healthcare、PerkinElmer Inc. 和 Danaher Corporation 等主要企業製定了嚴格的監管政策和品質標準,推動了該地區的成長。
According to Stratistics MRC, the Global Western Blotting Market is accounted for $1.18 billion in 2023 and is expected to reach $2.11 billion by 2030 growing at a CAGR of 8.7% during the forecast period. Protein analysis and detection are common applications of the molecular biology technique known as western blotting. It involves transferring the separated proteins onto a membrane after they have been separated by size using gel electrophoresis. Numerous scientific domains utilize western blotting to aid in the investigation of protein expression, post-translational modifications, and interactions.
According to data published by the Centers for Disease Control and Prevention (CDC), stated that in 2020, 30,635 people received an HIV diagnosis in the U.S.
The study of cellular processes, protein expression, and interactions is greatly aided by western blotting, which provides important new understandings in fields like neurobiology and cancer. It is essential as the field of biomedical research grows and the need for precise protein analysis increases. Furthermore, its versatility in exploring diseases, understanding molecular mechanisms, and validating research findings positions it as a fundamental tool, to meet the evolving demands of the biomedical research community which is driving adoption and innovation of this market's growth.
The cost of Western blotting can be attributed to several reasons, such as the fact that the procedure necessitates the use of costly reagents and consumables, including blocking agents, detection substrates, and antibodies. Specialized tools like imaging equipment and gel electrophoresis systems also raise the overall cost. Furthermore, the cost of using the technique is further increased by the requirement for skilled personnel. The high expense of carrying out these tests is one significant obstacle to the market.
Initiatives from government bodies, such as the National Institutes of Health (NIH), allocate funds to projects involving Western blotting techniques. Innovation, technical progress, and the investigation of novel uses in biomedicine, medication development, and diagnostics are all encouraged by this support. Furthermore, the financial support creates a favorable environment for developments in protein analysis and related research, speeds up scientific discoveries, and supports by improving accessibility which is driving this market expansion.
Incompatibilities across laboratories in procedures, reagents, and equipment hinder result reproducibility. Variability in methodologies impacts data reliability, making it challenging for researchers to compare and validate findings. Problems with standardization can damage Western blotting's image, raising doubts regarding the accuracy of the data and making it more difficult for research groups to collaborate.
Disruptions in supply chains, logistical challenges, and restrictions on laboratory activities have hindered the production and distribution of Western blotting reagents and instruments. Many research projects were delayed or halted due to lockdowns, impacting the demand for these products. Furthermore, the resources available for Western blotting studies have been restricted due to decreased funding for research irrelevant to COVID-19. Eventually, attention and resources have been diverted from other areas due to the shift in research priorities towards COVID-19. Economic uncertainties have prompted cost-consciousness, affecting purchasing decisions in the scientific community.
The instrument segment is estimated to hold the largest share due to its crucial role in molecular biology and protein research. They play a pivotal role in the precise separation, transfer, and detection of proteins from complex biological samples. Manufacturers continually innovate to provide researchers with state-of-the-art systems, incorporating features like rapid electrophoresis, semi-dry or wet transfer capabilities, and advanced imaging technologies. Furthermore, these instruments include electrophoresis systems for separating proteins based on size, transfer systems for transferring proteins, and imaging systems for visualizing and quantifying protein bands, which is driving this segment expansion.
The biopharmaceutical & biotechnology companies segment is anticipated to have highest CAGR during the forecast period due to the use of these companies for protein analysis in drug development, quality control, and research processes. The technique aids in assessing protein expression, validating therapeutic targets, and ensuring product consistency. Additionally, by providing precise insights into protein characteristics, it supports the development of biopharmaceuticals and the advancement of biotechnological research. It represents a key stakeholder group in the development and production of biotherapeutics, thereby boosting this segment's growth.
North America commanded the largest market share during the extrapolated period owing to government programs that support scientific research and development, especially in the biotechnology and healthcare sectors. Collaborations between academic institutions, research organizations, and industry players foster innovation and applications. Furthermore, these now meet quality standards set by regulatory frameworks established by organizations such as the Food and Drug Administration (FDA), guaranteeing dependability in research and diagnostics, thereby propelling this region's size.
Europe is expected to witness highest CAGR over the projection period due to advancements in detection technologies, transfer strategies, and gel electrophoresis systems in life sciences research. These procedures are now more accurate and efficient European policies promoting research and development, coupled with initiatives supporting biotechnology and healthcare innovation. Some of the key players including Boster Biological Technology, GE Healthcare, PerkinElmer Inc. and Danaher Corporation contribute to strict regulatory policies and quality standards which are driving this region's growth.
Some of the key players in the Western Blotting Market include Abcam Plc, Advansta, Inc., Azure biosystems, inc., Bio-Techne Corporation, Boster Biological Technology, Cell signaling technology, inc., Danaher Corporation, EMD Millipore Corporation, GE Healthcare, Hofmann-La Roche Ltd., LI-COR, Inc., Merck Kgaa, PerkinElmer Inc., Stressmarq biosciences inc. and Thermo Fisher Scientific, Inc.
In November 2023, GE HealthCare and Masimo announced a joint agreement to integrate Masimo Signal Extraction Technology (SET) pulse oximetry into GE HealthCare's Portrait Mobile wireless and wearable patient monitoring solution.
In October 2023, Thermo Fisher Scientific and Olink announced that their respective boards of directors have approved Thermo Fisher's proposal to acquire Olink for $26.00 per common share in cash, representing $26.00 per American Depositary Share (ADS) in cash.
In October 2023, GE HealthCare Announces New Innovations and Collaborations in Image Guided Therapy as part of TCT2023 Cardiology Care Pathway Showcase. As clinicians work to treat CVD, cardiology procedures continue to evolve as demand for minimally invasive surgery grows.